3-aminobenzamide and bms 536924

3-aminobenzamide has been researched along with bms 536924 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beauchamp, MC; Carboni, JM; Gotlieb, WH; Gottardis, MM; Knafo, A; Pollak, MN; Yasmeen, A	1

Other Studies

1 other study(ies) available for 3-aminobenzamide and bms 536924

Article	Year
BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecologic oncology, 2009, Volume: 115, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzimidazoles; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Oncogene Protein v-akt; Ovarian Neoplasms; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Pyridones; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases	2009

Article

Year

BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.

Gynecologic oncology, 2009, Volume: 115, Issue:2

Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzimidazoles; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Oncogene Protein v-akt; Ovarian Neoplasms; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Pyridones; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases

2009